Latest filing published 05 Mar 2024 for Phio Pharmaceuticals Corp., €297.
Insider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Caitlin Kontulis: trading record in brief
All filings by Caitlin Kontulis on record concern Phio Pharmaceuticals Corp., in the capacity of senior executive. Over a trading history stretching from 1 August 2018 to 1 March 2024, the count stands at 13 filings.
The filings describe grants, exercises and other transfers rather than trades on the open market. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
The newest entry dates from 5 March 2024: a share grant of €297, in Phio Pharmaceuticals Corp. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. The legal deadline for a Form 4 is two business days after the transaction. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Caitlin Kontulis
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 335 shares@ US$0.9583.5% of flowCommon stock, $0.0001 par valueSEC:0001683168-24-001324:0
- 658 shares@ US$0.654.7% of flowCommon stock, $0.0001 par valueSEC:0001683168-24-001086:0
- 335 shares@ US$5.4920.3% of flowCommon stock, $0.0001 par valueSEC:0001209191-23-015880:0
- 4,500 shares0Common stock, $0.0001 par valueSEC:0001209191-23-011911:0
- 657 shares@ US$5.2037.2% of flowCommon stock, $0.0001 par valueSEC:0001209191-23-010876:0
- 4,011 shares@ US$0.82134.3% of flowCommon stock, $0.0001 par valueSEC:0001209191-22-015894:0
- 68,000 shares0Common stock, $0.0001 par valueSEC:0001209191-22-010402:0
7 of 7 declarations
